Streetbeat News

Analyst Ratings

WISH

Citigroup analyst Arren Cyganovich has maintained a 'Sell' rating on ContextLogic (NASDAQ:WISH) and lowered the price target from $7 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 3:41 pm

DKNG

DraftKings Inc (NASDAQ:DKNG) is on a quicker and more visible path to profitability, according to Truist Securities analyst Barry Jonas. He upgraded the rating for DraftKings from Hold to Buy and raised the price target from $31 to $44. The company's Q2 results were significantly better than consensus estimates. DraftKings is expected to benefit from a more rational promo and marketing environment and could continue to gain market share.

Portfolio Pulse from Priya Nigam

August 08, 2023 | 3:41 pm

CLLS

Oppenheimer analyst Hartaj Singh has reiterated an 'Outperform' rating on Cellectis (NASDAQ:CLLS) and maintained a price target of $11.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 3:41 pm

AYX

Oppenheimer analyst Ittai Kidron has maintained an 'Outperform' rating on Alteryx (NYSE:AYX), but lowered the price target from $65 to $55.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 3:39 pm

WTW

Willis Towers Watson Public Limited shares are trading lower after BMO Capital downgraded the stock from Market Perform to Underperform and lowered its price target from $230 to $205.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 3:38 pm

VCTR

RBC Capital analyst Kenneth Lee maintains an Outperform rating on Victory Capital Holdings (NASDAQ:VCTR) and raises the price target from $38 to $40.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 3:37 pm

USM

JP Morgan has upgraded United States Cellular's stock from Neutral to Overweight, leading to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 3:37 pm

SAGE

RBC Capital analyst Brian Abrahams has reiterated a 'Sector Perform' rating on Sage Therapeutics, maintaining a price target of $25.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 3:36 pm

PLRX

RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on Pliant Therapeutics (NASDAQ:PLRX), maintaining a price target of $57.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 3:35 pm

PAA

RBC Capital analyst Elvira Scotto maintains a 'Sector Perform' rating on Plains All American (NASDAQ:PAA) and raises the price target from $14 to $15.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 3:34 pm